From: Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of ‘deep’ product reviews
Trial
Southern Hemisphere (NAIB3001)
Europe (NAIB3002)
North America (NAIA3002)
Complications
Placebo
30%
33%
22%
Zanamivir
24%
15%
P value
0.24
0.125
0.049*
Antibiotics use
28%
17%
26%
11%
0.58
0.21
0.16